Therapies with sulfasalazine, salicylates, or PJ34 do not normalize the alterations in body weight, blood glucose, and GHb levels in experimentally diabetic rats
Body wt (g) | Blood glucose (mg/dl) | GHb (%) | |
---|---|---|---|
9 months | |||
Normal | 609 ± 58 | 76 ± 11 | 4.0 ± 0.2 |
Diabetic | 304 ± 48* | 325 ± 30* | 9.0 ± 1.1* |
Diabetic + sulfasalazine | 300 ± 36* | 344 ± 1* | 9.9 ± 0.7* |
3 months (experiment 1) | |||
Normal | 449 ± 20 | 109 ± 12 | 3.7 ± 0.1 |
Diabetic | 267 ± 31* | 281 ± 43* | 9.1 ± 1.2* |
Diabetic + sulfasalazine | 263 ± 30* | 314 ± 25* | 7.7 ± 1.3* |
Diabetic + sodium salicylate | 269 ± 29* | 299 ± 23* | 7.6 ± 0.5* |
Diabetic + buffered aspirin | 257 ± 24* | 314 ± 33* | 8.1 ± 1.1* |
3 months (experiment 2) | |||
Normal | 458 ± 14 | 122 ± 1 | 3.8 ± 0.2 |
Diabetic | 276 ± 42* | 291 ± 39* | 9.2 ± 0.9* |
Diabetic + sulfasalazine | 256 ± 18* | 293 ± 1* | 9.2 ± 2.0* |
Diabetic + PJ34 | 263 ± 28* | 287 ± 61* | 9.2 ± 1.1* |
Data are means ± SD of 6–10 animals.
* Significantly different from normal rats at P < 0.01 (ANOVA followed by Dunnett's test).